Improving drug effectiveness by controlling molecular structure
Stereochemical Editing of Quaternary Stereocenters Enabled by Enantioselective Recombination of C–C Bonds
['FUNDING_FELLOWSHIP'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11044034
This study is exploring a new way to make medicines work better and have fewer side effects by carefully changing their molecular structure, which could help improve treatments for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11044034 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of pharmaceutical drugs by precisely controlling their molecular structure, specifically targeting quaternary stereocenters. It aims to develop a new method for stereochemical editing that allows for the selective modification of these complex molecules using advanced techniques in synthetic organic chemistry. By employing a dual catalytic system that combines photoredox and nickel catalysis, the researchers hope to create a more efficient way to achieve the desired stereochemistry in drug compounds. This could lead to improved drug efficacy and reduced side effects for patients.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include patients who require medications with specific stereochemical properties for optimal therapeutic effects.
Not a fit: Patients who are not taking medications that rely on stereochemical properties may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer drugs tailored to individual patient needs.
How similar studies have performed: Other research has shown promise in using catalytic methods for stereochemical editing, indicating that this approach could be a significant advancement in drug development.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HWANG, TAEHWAN — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: HWANG, TAEHWAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.